TMPRSS2 and prostate cancer: Therefore, in prostate cancers with the TMPRSS2-ERG fusion oncogene, activation of AR signaling upregulates the expression of this fusion oncoprotein, leading to enhanced proliferation and survival and prostate cancer cells [10][11].